Advertisement

Investigation

  • A. J. Larner
Chapter
First Online:

Abstract

This chapter examines the utility of various investigative techniques in the diagnosis of cognitive disorders including, in order of increasing invasiveness, neuroimaging, neurogenetics, neurophysiology, cerebrospinal fluid analysis, and tissue diagnosis.

Keywords

Dementia Diagnosis Investigation Neuroimaging Neurogenetics Neurophysiology Cerebrospinal fluid 
This is a preview of subscription content, log in to check access.

References

  1. Adab N, Larner AJ. Adult-onset seizure disorder in 18q deletion syndrome. J Neurol. 2006;253:527–8.PubMedCrossRefGoogle Scholar
  2. Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008;300:1774–83.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Aji BM, Medley G, O’Driscoll K, Larner AJ, Alusi SH. Perry syndrome: a disorder to consider in the differential diagnosis of parkinsonism. J Neurol Sci. 2013a;330:117–8.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Aji BM, Fratalia L, Alusi SH, Larner AJ. Perry syndrome: more common than previously thought and associated with early cognitive impairment. Abstract Book. Integration by Translation. XX World Congress on Parkinson’s Disease and Related Disorders, Geneva, Switzerland, 8–11 December; 2013b. p. 106–7 (abstract 393).Google Scholar
  5. Aji BM, Milburn-McNulty P, Larner AJ. Epilepsy: when family history holds the key to diagnosis. Prog Neurol Psychiatry. 2016;20(5):11–2.CrossRefGoogle Scholar
  6. Ali R, Larner AJ, Doran M. L-dopa responsive suspected dementia. Eur J Neurol. 2010;17(Suppl 3):371 (abstract P2054).Google Scholar
  7. Ali R, Barborie A, Larner AJ, White RP. Psychiatric presentation of sporadic Creutzfeldt-Jakob disease: a challenge to current diagnostic criteria. J Neuropsychiatry Clin Neurosci. 2013;25:335–8.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Allison RS. The senile brain. A clinical study. London: Edward Arnold; 1962.Google Scholar
  9. Alzheimer Disease and Frontotemporal Dementia Mutation Database. 2017. http://www.molgen.ua.ac.be/Admutations. Accessed 10 Aug 2017.
  10. Anonymous. Practice parameter for diagnosis and evaluation of dementia. (summary statement) Report of the Quality Standards Subcommitte of the American Academy of Neurology. Neurology. 1994;44:2203–6.CrossRefGoogle Scholar
  11. Ansell G, Rotblat J. Radioactive iodine as a diagnostic aid for intrathoracic goitre. Br J Radiol. 1948;21:552–8.PubMedCrossRefGoogle Scholar
  12. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496–503.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Barkhof F, Fox NC, Bastos-Leite AJ, Scheltens P. Neuroimaging in dementia. Berlin: Springer; 2011.CrossRefGoogle Scholar
  14. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131–44.PubMedCrossRefGoogle Scholar
  15. Bonello M, Larner AJ, Marson AG. Profound amnesia after temporal lobectomy: an autoimmune process resembling patient H.M.? Case Rep Neurol. 2014;6:251–5.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Brickell KL, Steinbart EJ, Rumbaugh M, et al. Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease. Arch Neurol. 2006;63:1307–11.PubMedCrossRefGoogle Scholar
  17. Brown J, Wiggins J, Dong H, Harvey R, Richardson F, Dawson K, Parker RA. The H-TYM. Evaluation of a short cognitive test to detect mild AD and amnestic MCI. Int J Geriatr Psychiatry. 2014;29:272–80.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Bullock R, Qizilbash N. Memory clinics—a guide to implementation and evaluation. In: Qizilbash N, Schneider LS, Chui H et al. editors. Evidence-based dementia practice. Oxford: Blackwell; 2002. p. 828–43.Google Scholar
  19. Burton EJ, Barber R, Mukaetova-Ladinska EB, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer’s disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain. 2009;132:195–203.PubMedCrossRefGoogle Scholar
  20. Chan D, Walters RJ, Sampson EL, Schott JM, Smith SJ, Rossor MN. EEG abnormalities in frontotemporal lobar degeneration. Neurology. 2004;62:1628–30.PubMedCrossRefGoogle Scholar
  21. Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry. 2012;83:124–37.PubMedCrossRefGoogle Scholar
  22. Charpentier P, Lavenu I, Defebvre L, Duhamel A, Lecouffe P, Pasquier F, Steinling M. Alzheimer’s disease and frontotemporal dementia are differentiated by discriminant analysis applied to (99m)Tc HmPAO SPECT data. J Neurol Neurosurg Psychiatry. 2000;69:661–3.PubMedPubMedCentralCrossRefGoogle Scholar
  23. Chouery E, Delague V, Bergougnoux A, Koussa S, Serre JL, Megarbane A. Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Hum Mutat. 2008;29:E194–204.PubMedCrossRefGoogle Scholar
  24. Clarfield AM. The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med. 2003;163:2219–29.PubMedCrossRefGoogle Scholar
  25. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275–83.PubMedCrossRefGoogle Scholar
  26. Colloby SJ, McParland S, O’Brien JT, Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias. Brain. 2012;135:2798–808.PubMedCrossRefGoogle Scholar
  27. Colombo R, Tavian D, Baker MC, Richardson AM, Snowden JS, Neary D, Mann DM, Pickering-Brown SM. Recent origin and spread of a common Welsh MAPT splice mutation causing frontotemporal lobar degeneration. Neurogenetics. 2009;10:313–8.PubMedCrossRefGoogle Scholar
  28. Connon P, Larner AJ. Fragile X-associated tremor/ataxia syndrome: cognitive presentations. Br J Hosp Med. 2017;78:230–1.CrossRefGoogle Scholar
  29. Cronin-Stubbs D, Beckett LA, Scherr PA, et al. Weight loss in people with Alzheimer’s disease: a prospective population based analysis. BMJ. 1997;314:178–9.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Cruts M, van Duijn CM, Backhovens H, et al. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet. 1998;7:43–51.PubMedPubMedCentralCrossRefGoogle Scholar
  31. Davies M, Larner AJ. Clinical misdiagnosis of Alzheimer’s disease: getting it wrong again. Eur J Neurol. 2009;16(Suppl 3):351 (abstract 2036).Google Scholar
  32. Davies RR, Kipps CM, Mitchell J, Kril JJ, Halliday GM, Hodges JR. Progression in frontotemporal dementia: identifying a benign behavioral variant by magnetic resonance imaging. Arch Neurol. 2006;63:1627–31.PubMedCrossRefGoogle Scholar
  33. Davies RR, Doran M, Larner AJ. Early-onset dementia. Prog Neurol Psychiatry. 2011;15(4):12–6.CrossRefGoogle Scholar
  34. Dawe G. The diagnostic yield of CT brain scans in patients referred to memory loss clinic. Dement Geriatr Cogn Disord. 2012;34(Suppl1):126.Google Scholar
  35. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucelotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–56.PubMedPubMedCentralCrossRefGoogle Scholar
  36. Doran M. Diagnosis of presenile dementia. Br J Hosp Med. 1997;58:105–10.PubMedPubMedCentralGoogle Scholar
  37. Doran M, Larner AJ. Monozygotic twins discordant for primary progressive aphasia. Alzheimer Dis Assoc Disord. 2004a;18:48–9.PubMedCrossRefGoogle Scholar
  38. Doran M, Larner AJ. Prominent behavioural and psychiatric symptoms in early-onset Alzheimer’s disease in a sib pair with the presenilin-1 gene R269G mutation. Eur Arch Psychiatry Clin Neurosci. 2004b;254:187–9.PubMedCrossRefGoogle Scholar
  39. Doran M, Larner AJ. EEG findings in dementia with Lewy bodies causing diagnostic confusion with sporadic Creutzfeldt-Jakob disease. Eur J Neurol. 2004c;11:838–41.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Doran M, Larner AJ. Familial Alzheimer’s disease due to presenilin-1 Y115C mutation. J Neurol. 2006;253(Suppl 2):II91 (Poster P359).Google Scholar
  41. Doran M, Larner AJ. Monogenic Mendelian causes of dementia: ten-year survey of a dementia clinic. Eur J Neurol. 2009;16(Suppl3):291 (abstract P1731).Google Scholar
  42. Doran M, du Plessis DG, Enevoldson TP, Fletcher NA, Ghadiali E, Larner AJ. Pathological heterogeneity of clinically diagnosed corticobasal degeneration. J Neurol Sci. 2003;216:127–34.PubMedCrossRefGoogle Scholar
  43. Doran M, Vinjamuri S, Collins J, Parker D, Larner AJ. SPECT perfusion imaging in the differential diagnosis of dementia: a retrospective regional audit. Int J Clin Pract. 2005a;59:496–500.PubMedCrossRefGoogle Scholar
  44. Doran M, Enevoldson TP, Ghadiali EJ, Larner AJ. Mills syndrome with dementia: broadening the phenotype of FTD/MND. J Neurol. 2005b;252:846–7.PubMedCrossRefGoogle Scholar
  45. Doran M, du Plessis DG, Ghadiali EJ, Mann DMA, Pickering-Brown S, Larner AJ. Familial early-onset dementia with tau intron 10 +16 mutation with clinical features similar to those of Alzheimer disease. Arch Neurol. 2007;64:1535–9.PubMedPubMedCentralCrossRefGoogle Scholar
  46. Dougall NJ, Bruggink S, Ebmeier KP. The clinical use of 99mTc-HMPAO-SPECT in Alzheimer’s disease. A systematic review. In: Ebmeier KP, editor. SPECT in dementia. Basel: Karger; 2003. p. 4–37.CrossRefGoogle Scholar
  47. Du Plessis DG, Larner AJ. Phenotypic similarities causing clinical misdiagnosis of pathologically-confirmed sporadic Creutzfeldt-Jakob disease as dementia with Lewy bodies. Clin Neurol Neurosurg. 2008;110:194–7.PubMedCrossRefGoogle Scholar
  48. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734–46.PubMedPubMedCentralCrossRefGoogle Scholar
  49. Dubois B, Feldman HH, Jacova C et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29. [Erratum Lancet Neurol. 2014;13:757].Google Scholar
  50. Farrer MJ, Hulihan MM, Kachergus JM, et al. DCTN1 mutations in Perry syndrome. Nat Genet. 2009;41:163–5.PubMedPubMedCentralCrossRefGoogle Scholar
  51. Filippi M, Agosta F, Barkhof F, et al. EFNS task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol. 2012;19:e131–40.PubMedCrossRefGoogle Scholar
  52. Filley CM. The behavioral neurology of white matter. 2nd ed. Oxford: Oxford University Press; 2012.Google Scholar
  53. Frisoni GB, Fox NC, Jack CRJ, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6:67–77.PubMedPubMedCentralCrossRefGoogle Scholar
  54. Genova L. Still Alice. London: Simon and Schuster; 2007.Google Scholar
  55. Ghadiri-Sani M, Larner AJ, Menon RK. Sensory neuronopathy as a possible paraneoplastic neurological syndrome linked with pancreatic cancer. Br J Hosp Med. 2016;77:48–9.CrossRefGoogle Scholar
  56. Giraldo M, Lopera F, Siniard AL, et al. Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer’s disease. Neurobiol Aging. 2013;34:2077.PubMedCrossRefGoogle Scholar
  57. Goldman JS, Farmer JM, Wood EM, et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology. 2005;65:1817–9.PubMedPubMedCentralCrossRefGoogle Scholar
  58. Goldman JS, Hahn SE, Catania JW, et al. Genetic counselling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med. 2011a;13:597–605.PubMedPubMedCentralCrossRefGoogle Scholar
  59. Goldman JS, Rademakers R, Huey ED, Boxer AL, Mayeux R, Miller BL, Boeve BF. An algorithm for genetic testing of frontotemporal lobar degeneration. Neurology. 2011b;76:475–83.PubMedPubMedCentralCrossRefGoogle Scholar
  60. Golomb J, Wisoff J, Miller DC, Boksay I, Kluger A, Weiner H, Salton J, Graves W. Alzheimer’s disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response. J Neurol Neurosurg Psychiatry. 2000;68:778–81.PubMedPubMedCentralCrossRefGoogle Scholar
  61. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2672–713.PubMedPubMedCentralCrossRefGoogle Scholar
  62. Guerreiro RJ, Lohmann E, Bras JM, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013;70:78–84.PubMedPubMedCentralCrossRefGoogle Scholar
  63. Hall B, Mak E, Cervenka S, Aigbirhio FI, Rowe JB, O’Brien JT. In vivo tau PET imaging in dementia: pathophysiology, radiotracer quantification, and a systematic review of clinical findings. Ageing Res Rev. 2017;36:50–63.PubMedCrossRefGoogle Scholar
  64. Hamilton R, Patel S, Lee EB, et al. Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Ann Neurol. 2010;68:535–40.PubMedPubMedCentralCrossRefGoogle Scholar
  65. Hancock P, Larner AJ. Late-onset autosomal dominant Alzheimer’s disease. Eur J Neurol. 2007;14(Suppl1):187–8. (abstract P2102).Google Scholar
  66. Hancock P, Larner AJ. A case of frontotemporal lobar degeneration with MND. Prog Neurol Psychiatry. 2008;12(3):15,18.Google Scholar
  67. Hejl A, Høgh P, Waldemar G. Potentially reversible conditions in 1000 consecutive memory clinic patients. J Neurol Neurosurg Psychiatry. 2002;73:390–4.PubMedPubMedCentralCrossRefGoogle Scholar
  68. Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet. 1999;353:183–9.PubMedCrossRefGoogle Scholar
  69. Hodges JR, Davies R, Xuereb J, Kril J, Halliday G. Survival in frontotemporal dementia. Neurology. 2003;61:349–54.PubMedCrossRefGoogle Scholar
  70. Hort J, O’Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol. 2010a;17:1236–48.PubMedCrossRefGoogle Scholar
  71. Hort J, Bartos A, Pirttila T, Scheltens P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur J Neurol. 2010b;17:90–6.PubMedCrossRefGoogle Scholar
  72. Ibrahim I, Young CA, Larner AJ. Fornix damage from solitary subependymal giant cell astrocytoma causing postoperative amnesic syndrome. Br J Hosp Med. 2009;70:478–9.CrossRefGoogle Scholar
  73. Isaacs AM, Johannsen P, Holm I, Nielsen JE, FReJA Consortium. Frontotemporal dementia caused by CHMP2B mutations. Curr Alzheimer Res. 2011;8:246–51.PubMedPubMedCentralCrossRefGoogle Scholar
  74. Jagust W, D’Esposito M, editors. Imaging the aging brain. Oxford: Oxford University Press; 2009.Google Scholar
  75. Janssen JC, Godbolt AK, Ioannidis P, Thompson EJ, Rossor MN. The prevalence of oligoclonal bands in the CSF of patients with primary neurodegenerative dementia. J Neurol. 2004;251:184–8.PubMedCrossRefGoogle Scholar
  76. Jayaratnam S, Khoo AK, Basic D. Rapidly progressive Alzheimer’s disease and elevated 14-3-3 proteins in cerebrospinal fluid. Age Ageing. 2008;37:467–9.PubMedCrossRefGoogle Scholar
  77. Jelic V, Kowlaski J. Evidence-based evaluation of diagnostic accuracy of resting EEG in dementia and mild cognitive impairment. Clin EEG Neurosci. 2009;40:129–42.PubMedCrossRefGoogle Scholar
  78. Jesse S, Brettschneider J, Sussmuth SD, et al. Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases. J Neurol. 2011;258:1034–41.PubMedCrossRefGoogle Scholar
  79. Jimenez-Escrig A, Gomez-Tortosa E, Baron M, et al. A multigenerational pedigree of late-onset Alzheimer’s disease implies new genetic causes. Brain. 2005;128:1707–15.PubMedCrossRefGoogle Scholar
  80. Kantarci K. 1H magnetic resonance spectroscopy in dementia. Br J Radiol. 2007;80(SpecNo 2):S146–52.PubMedCrossRefGoogle Scholar
  81. Klünemann HH, Ridha BH, Magy L, et al. The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology. 2005;64:1502–7.PubMedCrossRefGoogle Scholar
  82. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306–19.PubMedCrossRefGoogle Scholar
  83. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143–53.CrossRefPubMedGoogle Scholar
  84. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75:230–8.PubMedPubMedCentralCrossRefGoogle Scholar
  85. Larner AJ. Missed diagnosis of vitamin B12 deficiency presenting with paraesthetic symptoms. Int J Clin Pract. 2002;56:377–8.PubMedGoogle Scholar
  86. Larner AJ. Adult-onset dementia with prominent frontal lobe dysfunction in X-linked adrenoleukodystrophy with R152C mutation in ABCD1 gene. J Neurol. 2003;250:1253–4.PubMedCrossRefGoogle Scholar
  87. Larner AJ. Getting it wrong: the clinical misdiagnosis of Alzheimer’s disease. Int J Clin Pract. 2004a;58:1092–4.PubMedCrossRefGoogle Scholar
  88. Larner AJ. Visual failure caused by vitamin B12 deficiency optic neuropathy. Int J Clin Pract. 2004b;58:977–8.PubMedCrossRefGoogle Scholar
  89. Larner AJ. Genotype-phenotype correlations in early-onset Alzheimer disease with presenilin 1 gene mutations. Arch Neurol. 2004c;61:801.PubMedCrossRefGoogle Scholar
  90. Larner AJ. Proton magnetic resonance spectroscopy (1H-MRS): audit of pragmatic use in the Cognitive Function Clinic. J Neurol. 2006;253(Suppl 2):II92. (abstract P363).Google Scholar
  91. Larner AJ. Down syndrome in the neurology clinic: Too much? Too little? Too late? Down Syndr Res Pract. 2007a;12:69–71.CrossRefGoogle Scholar
  92. Larner AJ. Integrated care pathways in dementia: a challenge to National Institute for Health and Clinical Excellence/Social Care Institute for Excellence guidance. J Integrated Care Pathways. 2007b;11:95–9.CrossRefGoogle Scholar
  93. Larner AJ. Neuropsychological neurology: the neurocognitive impairments of neurological disorders. Cambridge: Cambridge University Press; 2008a.CrossRefGoogle Scholar
  94. Larner AJ. Proton magnetic resonance spectroscopy (1H-MRS): pragmatic study of Alzheimer’s disease and frontotemporal dementia. Eur J Neurol. 2008b;15(Suppl 3):283. (abstract P2287).Google Scholar
  95. Larner AJ. Monogenic Mendelian disorders in general neurological practice. Int J Clin Pract. 2008c;62:744–6.PubMedCrossRefGoogle Scholar
  96. Larner AJ. Mutation negative early-onset familial Alzheimer disease: consider screening for tau gene mutations. Alzheimer Dis Assoc Disord. 2008d;22:194–5.PubMedCrossRefGoogle Scholar
  97. Larner AJ. Asymptomatic X-linked adrenoleukodystrophy with the R152C mutation: neuropsychological and neuroimaging findings. Eur J Neurol. 2008e;15(Suppl 3):293. (abstract P2323).Google Scholar
  98. Larner AJ. Delusion of pregnancy in frontotemporal lobar degeneration with motor neurone disease (FTLD/MND). Behav Neurol. 2008f;19:199–200.PubMedPubMedCentralCrossRefGoogle Scholar
  99. Larner AJ. A 50-year old man with deteriorating cognitive function and impaired movement. PLoS Med. 2009a;6(1):e1000019.CrossRefGoogle Scholar
  100. Larner AJ. Deletion of 18q. In: Lang F, editor. Encyclopedia of molecular mechanisms of disease (3 volumes). Berlin: Springer; 2009b. p. 503–4.Google Scholar
  101. Larner AJ. Intrafamilial clinical phenotypic heterogeneity with MAPT gene splice site IVS10+16C>T mutation. J Neurol Sci. 2009c;287:253–6.PubMedPubMedCentralCrossRefGoogle Scholar
  102. Larner AJ. What’s new in dementia? Clin Med. 2010;10:391–4.CrossRefGoogle Scholar
  103. Larner AJ. Audit of practice versus guidelines: neuro-imaging in a dementia clinic. Morecambe Bay Med J. 2011a;6:110–2.Google Scholar
  104. Larner AJ. Presenilin 1 mutation Alzheimer’s disease: a genetic epilepsy syndrome? Epilepsy Behav. 2011b;21:20–2.PubMedCrossRefGoogle Scholar
  105. Larner AJ. Senile myoclonic epilepsy in Down syndrome. Seizure. 2011c;20:512.PubMedCrossRefGoogle Scholar
  106. Larner AJ. Camptodactyly: a 10-year series. Eur J Dermatol. 2011d;21:771–5.PubMedPubMedCentralGoogle Scholar
  107. Larner AJ. FTLD: a challenging diagnosis. Prog Neurol Psychiatry. 2011e;15(1):31.Google Scholar
  108. Larner AJ. FTDP-17: two-year follow-up of motor and cognitive features following autologous stem cell transplantation. J Neuropsychiatry Clin Neurosci. 2012;24:E1–2.PubMedCrossRefGoogle Scholar
  109. Larner AJ. Intrafamilial clinical phenotypic heterogeneity with progranulin gene p.Glu498fs mutation. J Neurol Sci. 2012b;316:189–90.PubMedPubMedCentralCrossRefGoogle Scholar
  110. Larner AJ. Ascertaining familial Alzheimer’s disease gene mutations. Prog Neurol Psychiatry. 2012c;16(6):6.Google Scholar
  111. Larner AJ. Neuropsychological neurology: the neurocognitive impairments of neurological disorders. 2nd ed. Cambridge: Cambridge University Press; 2013a.Google Scholar
  112. Larner AJ. Cerebral mass lesions presenting in a cognitive disorders clinic. Br J Hosp Med. 2013b;74:694–5.CrossRefGoogle Scholar
  113. Larner AJ. Presenilin-1 mutations in Alzheimer’s disease: an update on genotype-phenotype relationships. J Alzheimers Dis. 2013c;37:653–9.PubMedCrossRefGoogle Scholar
  114. Larner AJ. Delusion of pregnancy: a case revisited. Behav Neurol. 2013d;27:293–4.PubMedPubMedCentralCrossRefGoogle Scholar
  115. Larner AJ. Hard-TYM: a pragmatic study. Int J Geriatr Psychiatry. 2015;30:330–1.CrossRefPubMedPubMedCentralGoogle Scholar
  116. Larner AJ. Transient global amnesia. From patient encounter to clinical neuroscience. London: Springer; 2017a.CrossRefGoogle Scholar
  117. Larner AJ. FRONTIER Executive Screen (FES). Poster P0034, Association of British Neurologists Annual Meeting, Liverpool, 3–5 May, 2017b.Google Scholar
  118. Larner AJ, Doran M. Prion disease at a regional neuroscience centre: retrospective audit. J Neurol Neurosurg Psychiatry. 2004;75:1789–90.PubMedPubMedCentralCrossRefGoogle Scholar
  119. Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer’s disease associated with mutations of the presenilin-1 gene. J Neurol. 2006a;253:139–58.PubMedCrossRefGoogle Scholar
  120. Larner AJ, Doran M. Reply to Dr Raux et al.: molecular diagnosis of autosomal dominant early onset Alzheimer’s disease: an update (J Med Genet 2005;42:793-5). J Med Genet. 2006b;43:e44.PubMedPubMedCentralCrossRefGoogle Scholar
  121. Larner AJ, Doran M. Clinical heterogeneity associated with tau gene mutations. Eur Neurol Rev. 2009a;3(2):31–2.CrossRefGoogle Scholar
  122. Larner AJ, Doran M. Genotype-phenotype relationships of presenilin-1 mutations in Alzheimer’s disease: an update. J Alzheimers Dis. 2009b;17:259–65.PubMedCrossRefGoogle Scholar
  123. Larner AJ, Doran M. Inter- and intrafamilial clinical heterogeneity in FTDP-17 associated with MAPT 10+16 mutation. J Neurol Neurosurg Psychiatry. 2009c;80:e1.CrossRefGoogle Scholar
  124. Larner AJ, du Plessis DG. Early-onset Alzheimer’s disease with presenilin-1 M139V mutation: clinical, neuropsychological and neuropathological study. Eur J Neurol. 2003;10:319–23.PubMedCrossRefGoogle Scholar
  125. Larner AJ, Gardner-Thorpe C. Mills syndrome with dementia. Eur Neurol J. 2012;4(2):29–32.Google Scholar
  126. Larner AJ, Rakshi JS. Vitamin B12 deficiency and dementia. Eur J Neurol. 2001;8:730.PubMedCrossRefGoogle Scholar
  127. Larner AJ, Zeman AZ, Allen CM, Antoun NM. MRI appearances in subacute combined degeneration of the spinal cord due to vitamin B12 deficiency. J Neurol Neurosurg Psychiatry. 1997;62:99–100.PubMedPubMedCentralCrossRefGoogle Scholar
  128. Larner AJ, Janssen JC, Cipolotti L, Rossor MN. Cognitive profile in dementia associated with vitamin B12 deficiency due to pernicious anaemia. J Neurol. 1999;246:317–9.PubMedCrossRefGoogle Scholar
  129. Larner AJ, Smith ETS, Doran M. Does MRI/MRS permit ante mortem diagnosis of progressive subcortical gliosis of Neumann? J Neurol Neurosurg Psychiatry. 2003;74:404 (abstract 29). (Full paper at [www.acnr.co.uk/mar_apr_2009/MAR09_A_Larner.pdf]).
  130. Larner AJ, Ray PS, Doran M. The R269H mutation in presenilin-1 presenting as late-onset autosomal dominant Alzheimer’s disease. J Neurol Sci. 2007;252:173–6.PubMedPubMedCentralCrossRefGoogle Scholar
  131. Larner AJ, Coles AJ, Scolding NJ, Barker RA. A-Z of neurological practice. A guide to clinical neurology. 2nd ed. London: Springer; 2011.Google Scholar
  132. Larner MJ, Larner AJ. Normal pressure hydrocephalus: false positives. Pract Neurol. 2006;6:264.CrossRefGoogle Scholar
  133. Le Ber I, Camuzat A, Guillot-Noel L, et al. C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testing. J Alzheimers Dis. 2013;34:485–99.Google Scholar
  134. Liyanagedera S, Bracewell RM, Larner AJ. Diagnosing dementia with Lewy bodies: new diagnostic criteria. J R Coll Phys Edinb. 2018;48:44–5.CrossRefGoogle Scholar
  135. Lladó A, Fortea J, Ojea T, Bosch B, Sanz P, Valls-Solé J, Clarimon J, Molinuevo JL, Sánchez-Valle R. A novel PSEN1 mutation (K239N) associated with Alzheimer’s disease with wide range age of onset and slow progression. Eur J Neurol. 2010;17:994–6.PubMedCrossRefGoogle Scholar
  136. Lobotesis K, Fenwick DJ, Phipps A, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology. 2001;56:643–9.PubMedCrossRefGoogle Scholar
  137. Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59:1077–9.PubMedCrossRefGoogle Scholar
  138. Magdalinou NK, Ling H, Shand Smith JD, et al. Normal pressure hydrocephalus or progressive supranuclear palsy? A clinicopathological case series. J Neurol. 2013;260:1009–13.PubMedCrossRefGoogle Scholar
  139. Malm J, Eklund A. Idiopathic normal pressure hydrocephalus. Pract Neurol. 2006;6:14–27.CrossRefGoogle Scholar
  140. Mann DM. Calcification of the basal ganglia in Down’s syndrome and Alzheimer’s disease. Acta Neuropathol. 1988;76:595–8.PubMedCrossRefGoogle Scholar
  141. Marks M. Routine test batteries may not be cost effective. BMJ. 2011;343:d6330.PubMedCrossRefGoogle Scholar
  142. Marmarou A, Bergsneider M, Relkin N, Klinge P, Black PM. Development of guidelines for idiopathic normal-pressure hydrocephalus: introduction. Neurosurgery. 2005;57(3Suppl):S1–3.PubMedGoogle Scholar
  143. McCormick LJ, Larner AJ. “Could you repeat that?”: not always a hearing problem! Br J Hosp Med. 2018;79. (in press)Google Scholar
  144. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88–100.PubMedPubMedCentralCrossRefGoogle Scholar
  145. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.PubMedPubMedCentralCrossRefGoogle Scholar
  146. McNeil R, Sare GM, Manoharan M, et al. Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2007;78:350–5.CrossRefGoogle Scholar
  147. Menon R, Barborie A, Jaros E, Mann DMA, Ray PS, Larner AJ. What’s in a name? Neuronal intermediate filament inclusion disease (NIFID), frontotemporal lobar degeneration-intermediate filament (FTLD-IF) or frontotemporal lobar degeneration-fused in sarcoma (FTLD-FUS)? J Neurol Neurosurg Psychiatry. 2011;82:1412–4.PubMedCrossRefGoogle Scholar
  148. Milburn-McNulty P, Larner AJ. Transient global amnesia and brain tumour: chance concurrence or aetiological association? Case report and systematic literature review. Case Rep Neurol. 2015;7:18–25.PubMedPubMedCentralCrossRefGoogle Scholar
  149. Milburn-McNulty P, Larner AJ. Episodic loss of consciousness: when targeted genetic testing contributes to diagnosis. Prog Neurol Psychiatry. 2018;22. (in press)Google Scholar
  150. Mishima T, Fujioka S, Tomiyama H, et al. Establishing diagnostic criteria for Perry syndrome. J Neurol Neurosurg Psychiatry. 2018;89:482–7.PubMedCrossRefGoogle Scholar
  151. Morris Z, Whiteley WN, Longstreth WT, et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2009;339:547–50.Google Scholar
  152. Murray K, Ritchie DL, Bruce M, Young CA, Doran M, Ironside JW, Will RG. Sporadic Creutzfeldt-Jakob disease in two adolescents. J Neurol Neurosurg Psychiatry. 2008;79:14–8.PubMedCrossRefGoogle Scholar
  153. National Institute for Health and Clinical Excellence/Social Care Institute for Excellence. Dementia: supporting people with dementia and their carers in health and social care. NICE Clinical Guidance 42. London: National Institute for Health and Clinical Excellence; 2006. www.nice.org.uk/cG042.
  154. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–54.PubMedPubMedCentralCrossRefGoogle Scholar
  155. Neumann MA, Cohn R. Progressive subcortical gliosis, a rare form of presenile dementia. Brain. 1967;90:405–18.PubMedCrossRefGoogle Scholar
  156. Nicholl DJ, Greenstone MA, Clarke CE, et al. An English kindred with a novel recessive tauopathy and respiratory failure. Ann Neurol. 2003;54:682–6.PubMedCrossRefGoogle Scholar
  157. Nightingale S, Michael BD, Defres S, Benjamin LA, Solomon T. Test them all: an easily diagnosed and readily treatable cause of dementia with life-threatening consequences if missed. Pract Neurol. 2013;13:354–6.PubMedPubMedCentralCrossRefGoogle Scholar
  158. Nitrini R, Caixeta L. University educated man with childish behaviour. In: Gauthier S, Rosa-Neto P, editors. Case studies in dementia. Common and uncommon presentations. Cambridge: Cambridge University Press; 2011. p. 193–200.CrossRefGoogle Scholar
  159. Olde Rikkert MG, van der Vorm A, Burns A, et al. Consensus statement on genetic research in dementia. Am J Alzheimers Dis Other Demen. 2008;23:262–6.PubMedCrossRefGoogle Scholar
  160. Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313:1939–49.PubMedPubMedCentralCrossRefGoogle Scholar
  161. Perry TL, Bratty PJ, Hansen S, Kennedy J, Urquhart N, Dolman CL. Hereditary mental depression and parkinsonism with taurine deficiency. Arch Neurol. 1975;32:108–13.PubMedCrossRefGoogle Scholar
  162. Peters G, du Plessis DG, Humphrey PR. Cerebral Whipple’s disease with a stroke-like presentation and cerebrovascular pathology. J Neurol Neurosurg Psychiatry. 2002;73:336–9.PubMedPubMedCentralCrossRefGoogle Scholar
  163. Pickering-Brown SM, Richardson AMT, Snowden JS, et al. Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene. Brain. 2002;125:732–51.PubMedCrossRefGoogle Scholar
  164. Poblete-Gutierrez P, Wiederholt T, Martinez-Mir A, et al. Demystification of Chester porphyria: a nonsense mutation in the porphobilinogen deaminase gene. Physiol Res. 2006;55(Suppl2):S137–44.PubMedGoogle Scholar
  165. Pulhorn H, Quigley DG, Bosma JJ, Kirollos R, du Plessis DG, Jenkinson MD. Impact of brain biopsy on the management of patients with nonneoplastic undiagnosed neurological disorders. Neurosurgery. 2008;62:833–7.PubMedCrossRefGoogle Scholar
  166. Rademakers R, Dermaut B, Peeters K, et al. Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer disease does not share a common founder in Western Europe. Hum Mutat. 2003;22:409–11.PubMedCrossRefGoogle Scholar
  167. Randall A, Larner AJ. Late-onset cerebellar ataxia: don’t forget SCA 17. Eur J Neurol. 2016;23(Suppl1):696. (abstract P31191).Google Scholar
  168. Randall A, Ellis R, Hywel B, Davies RR, Alusi SH, Larner AJ. Rapid cognitive decline: not always Creutzfeldt-Jakob disease. J R Coll Physicians Edinb. 2015;45:209–12.PubMedCrossRefGoogle Scholar
  169. Randall A, Huda S, Jacob A, Larner AJ. Autoimmune encephalitis (NMDAR antibody) in a patient receiving post-transplant immunosuppression. Pract Neurol. 2018; pii: practneurol-2018-001923 [Epub ahead of print].Google Scholar
  170. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–77.PubMedPubMedCentralCrossRefGoogle Scholar
  171. Rawle MJ, Larner AJ. NARP syndrome: a 20-year follow-up. Case Rep Neurol. 2013;5:204–7.PubMedPubMedCentralCrossRefGoogle Scholar
  172. Renton AE, Majounie E, Waite A, et al. A hexanucelotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257–68.PubMedPubMedCentralCrossRefGoogle Scholar
  173. Roeber S, Bäzner H, Hennerici M, Porstmann R, Kretschmar HA. Neurodegeneration with features of NIFID and ALS – extended clinical and neuropathological spectrum. Brain Pathol. 2006;16:228–34.PubMedCrossRefGoogle Scholar
  174. Rohrer JD, Guerriero R, Vandrovcova J, et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009;73:1451–6.PubMedPubMedCentralCrossRefGoogle Scholar
  175. Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology. 1993;43:250–60.PubMedPubMedCentralCrossRefGoogle Scholar
  176. Rose FC. History of British neurology. London: Imperial College Press; 2012.Google Scholar
  177. Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. Lancet Neurol. 2010;9:793–806.PubMedPubMedCentralCrossRefGoogle Scholar
  178. Salmon E, Collette F, Garraux G. Differential diagnosis of dementia using functional neuroimaging. In: Jagust W, D’Esposito M, editors. Imaging the aging brain. New York: Oxford University Press; 2009. p. 245–60.CrossRefGoogle Scholar
  179. Sathasivam S, Doran M, Larner AJ. Frontotemporal lobar degeneration with motor neurone disease (FTLD/MND): presentations in psychiatric practice. Int J Psychiatry Clin Pract. 2008;12:138–41.PubMedCrossRefGoogle Scholar
  180. Schott JM. HIV testing in dementia: test some, perhaps more, but not all. Pract Neurol. 2013;13:357–8.PubMedCrossRefGoogle Scholar
  181. Schott JM, Williams DR, Butterworth RJ, Janssen JC, Larner AJ, Holton JL, Rossor MN. Shunt responsive progressive supranuclear palsy? Mov Disord. 2007;22:902–3.PubMedCrossRefGoogle Scholar
  182. Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82:476–86.PubMedCrossRefGoogle Scholar
  183. Sells RA, Larner AJ. Genetic causes of learning disability with epilepsy in the general neurology clinic. Eur J Neurol. 2011;18(Suppl2):184. (abstract P1315).Google Scholar
  184. Sheerin UM, Plagnol V, Bennett C, Dafalla B, Fryer A, Larner AJ, Revesz T, Homfray T, Wood NW. Exome sequencing reveals a novel DCTN1 mutation as the cause of Perry syndrome in a large British kindred—with expansion of the phenotype. 2018.Google Scholar
  185. Smithson E, Larner AJ. Glioblastoma multiforme masquerading as herpes simplex encephalitis. Br J Hosp Med. 2013;74:52–3.CrossRefGoogle Scholar
  186. Snowden JS, Thompson JC, Stopford CL, et al. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain. 2011;134:2478–92.PubMedCrossRefGoogle Scholar
  187. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS/ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012;19:1159–79, e85–90.PubMedCrossRefGoogle Scholar
  188. St John L, Larner AJ. Muscle wasting, bone pain and cognitive decline: a unifying diagnosis. Br J Hosp Med. 2015;76:602–3.CrossRefGoogle Scholar
  189. Steinhoff B, Zerr I, Glatting M, Schulz-Shaeffer W, Poser S, Kretschmar HA. Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol. 2004;56:702–8.PubMedCrossRefGoogle Scholar
  190. Stevens JC, Beck J, Lukic A, Ryan N, Abbs S, Collinge J, Fox NC, Mead S. Familial Alzheimer’s disease and inherited prion disease in the UK are poorly ascertained. J Neurol Neurosurg Psychiatry. 2011;82:1054–7.PubMedCrossRefGoogle Scholar
  191. Takashima S, Becker LE. Basal ganglia calcification in Down’s syndrome. J Neurol Neurosurg Psychiatry. 1985;48:61–4.PubMedPubMedCentralCrossRefGoogle Scholar
  192. Talbot PR, Lloyd JJ, Snowden JS, Neary D, Testa HJ. A clinical role for 99mTc-HMPAO SPECT in the investigation of dementia? J Neurol Neurosurg Psychiatry. 1998;64:306–13.PubMedPubMedCentralCrossRefGoogle Scholar
  193. Tolboom N, Koedam EL, Schott JM, et al. Dementia mimicking Alzheimer’s disease owing to a tau mutation: CSF and PET findings. Alzheimer Dis Assoc Disord. 2010;24:303–7.PubMedGoogle Scholar
  194. Utku U, Celik Y, Uyguner O, Yuksel-Apak M, Wollnik B. CADASIL syndrome in a large Turkish kindred caused by the R90C mutation in the Notch 3 receptor. Eur J Neurol. 2002;9:23–8.PubMedCrossRefGoogle Scholar
  195. van Straaten EC, Scheltens P, Knol DL, et al. Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. Stroke. 2003;34:1907–12.PubMedPubMedCentralCrossRefGoogle Scholar
  196. van Swieten JC, Heutink P. Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol. 2008;7:965–74.PubMedCrossRefGoogle Scholar
  197. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia. Eur J Neurol. 2007;14:e1–26.PubMedCrossRefGoogle Scholar
  198. Warren JD, Schott JM, Fox NC, et al. Brain biopsy in dementia. Brain. 2005;128:2016–25.PubMedCrossRefGoogle Scholar
  199. Watts GDJ, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36:377–81.PubMedCrossRefGoogle Scholar
  200. Wider C, Wszolek ZK. Rapidly progressive familial parkinsonism with central hypoventilation, depression and weight loss (Perry syndrome)—a literature review. Parkinsonism Relat Disord. 2008;14:1–7.PubMedCrossRefGoogle Scholar
  201. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain. 2005;128:1247–58.PubMedCrossRefGoogle Scholar
  202. Williamson J, Larner AJ. Young-onset cognitive decline: not always variant Creutzfeldt-Jakob disease. Eur J Neurol. 2016;23(Suppl1):368. (abstract P21049).Google Scholar
  203. Williamson JC, Larner AJ. Behavioural variant frontotemporal dementia with novel heterozygous TREM2 frameshift mutation. 2018.; submitted.Google Scholar
  204. Williamson JC, Higgs J, Fletcher NA, Larner AJ. Novel pathogenic ITM2B mutation or incidental benign sequence variant? Next Generation Sequencing conundrum. Poster, 4th Congress of the European Academy of Neurology, Lisbon, 16–19 June 2018.Google Scholar
  205. Wilson M, Doran M, Enevoldson TP, Larner AJ. Cognitive profiles associated with intracranial dural arteriovenous fistula. Age Ageing. 2010;39:389–92.CrossRefPubMedPubMedCentralGoogle Scholar
  206. Wojtowicz A, Schott JM, Larner AJ. CSF biomarkers and the diagnosis of variant forms of Alzheimer’s disease. Prog Neurol Psychiatry. 2017;21(2):13–5.CrossRefGoogle Scholar
  207. Wong SH, Lecky BRF, Steiger MJ. Parkinsonism and impulse control disorder: presentation of a new progranulin gene mutation. Mov Disord. 2009a;24:618–9.PubMedCrossRefGoogle Scholar
  208. Wong SH, Crooks D, Solomon T. How useful are brain biopsies in neurology patients? The Walton Centre experience. J Neurol Neurosurg Psychiatry. 2009b;80:452–3. (abstract 05).Google Scholar
  209. Wong SH, Saunders M, Larner AJ, Das K, Hart IK. An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis. J Neurol Neurosurg Psychiatry. 2010a;81:1167–9.PubMedPubMedCentralCrossRefGoogle Scholar
  210. Wong SH, Jenkinson MD, Faragher B, Thomas S, Crooks D, Solomon T. Brain biopsy in the management of neurology patients. Eur Neurol. 2010b;64:42–5.PubMedCrossRefGoogle Scholar
  211. Woolf SH, Kamerow DB. Testing for uncommon conditions. The heroic search for positive test results. Arch Intern Med. 1990;150:2451–8.PubMedCrossRefGoogle Scholar
  212. Youngs GR. La petite simulatrice: the story of the Chester porphyria. Med Historian. 1998;10:3–17.Google Scholar
  213. Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132:2659–68 [Erratum Brain. 2012;135:1335].PubMedPubMedCentralCrossRefGoogle Scholar
  214. Ziso B, Marsden D, Alusi S, Larner AJ. “Undifferentiated schizophrenia” revisited. J Neuropsychiatry Clin Neurosci. 2014;26:E62–3.PubMedCrossRefGoogle Scholar
  215. Ziso B, Larner AJ, Alusi SH. Stuck in the middle: Huntington’s disease or not Huntington’s disease? J Neuropsychiatry Clin Neurosci. 2015a;27:e85–6.PubMedCrossRefGoogle Scholar
  216. Ziso B, Williams TL, Walters RJL, Jaiser SR, Attems J, Wieshmann UC, Larner AJ, Jacob A. Facial onset sensory and motor neuronopathy: further evidence for a TDP-43 proteinopathy. Case Rep Neurol. 2015b;7:95–100.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • A. J. Larner
    • 1
  1. 1.Cognitive Function ClinicWalton Centre for Neurology and NeurosurgeryLiverpoolUK

Personalised recommendations

Cite chapter

Buy options